Posted by Michael Wonder on 08 Nov 2021
AZ announces US fast track designation for IL-5 inhibitor Fasenra
8 November 2021 - AstraZeneca’s IL-5 inhibitor Fasenra (benralizumab) has received a fast track designation from the US FDA for the treatment of eosinophilic gastritis, with or without eosinophilic gastro-enteritis.
The biologic treatment has also been granted orphan drug designations from the FDA for the treatment of eosinophilic gastritis and eosinophilic gastro-enteritis.
